US/UK/Canada

Share

Quotes

To be labeled exceptional by the European Commission is a great honor and an acknowledgement of the quality of the drug development process in Hamlet Pharma
Catharina Svanborg, Founder and Chairman of the Board.
Pick a time period -
Tags ( Active)

Positive Phase II study shows similar clinical outcomes of immunotherapy and antibiotic treatment for recurrent acute cystitis, potentially reducing the need for antibiotics

Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections - has successfully completed a controlled Phase II clinical trial in patients with recurrent acute cystitis (severe repeated infections of the urinary tract). The company now announces the outcome of a randomized Phase II study where patients were allocated to antibiotic treatment or anakinra, which is an Interleukin1 (IL-1) receptor antagonist (IL-1RA). The results show that most of the patients respond positively to the treatments and that the two treatments,

The Economist features groundbreaking research on human breast milk and the story of HAMLET

Hamlet BioPharma is pleased to announce a recent article about human breast milk in The Economist, a leading international newspaper. The article highlights the pioneering work on HAMLET being conducted at Lund University, exploring the remarkable therapeutic properties of breast milk components in treating cancer and other diseases. "This is important recognition of our findings and supports the relevance of our approach to developing novel cancer treatments." says Catharina Svanborg, Lund University and Hamlet BioPharma. Read the article in The Economist here: https://www.economist.

Alpha1H treatment shows strong effects in patients with bladder cancer in final analysis published in Cancer Medicine

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces that Hamlet BioPharma’s drug candidate Alpha1H has shown potent treatment effects on the majority of tumors in patients with cancer of the urinary bladder. The final analysis from placebo-controlled and dose-escalation studies is now published in Cancer Medicine, https://doi.org/10.1002/cam4.70149. The paper entitled ‘’Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer’’ presents data on all study endpoints, confirming the

Year-end Report (Q4) July 2023 – June 2024

OPENING REMARKS   The fiscal year 2023-2024 has been very productive, eventful and successful for Hamlet Biopharma, addressing the need for new treatment options in patients with cancer or severe bacterial infections. Financing was secured for the continued development of the company’s rich project portfolio. Progress in the cancer therapeutics area is shown by strong clinical data on the tumor response, FDA approval of the company’s IND and Fast Track status for Alpha1H. Significant clinical progress was made in the immuno-therapeutic Phase II studies, reported in patients with the

Invitation to monthly digital events and presentations of quarterly reports

Hamlet BioPharma is pleased to announce the continuation of the digital event series this autumn. These events provide participants a valuable opportunity to follow and discuss our drug development process and engage directly with our team during the Q&A sessions that will follow each presentation. Please visit our web page to join the digital events: https://hamletbiopharma.com/series-of-digital-events-2024/   The digital event are scheduled for: · September 18th, 2024, 12:00 CET · October 23rd, 2024, 12:00 CET · December 11th, 2024, 12:00 CET   Additionally, please

Hamlet BioPharma, the innovative pharmaceutical company, with a strong portfolio of projects, for the treatment of cancer and infections, is featured in this weekend issue of The Guardian

Hamlet BioPharma was selected by Media Planet, the media agency for The Guardian, to be featured in the Health Awareness campaign, BLADDER AND BOWEL HEALTH, given the innovative work conducted by the company.   The advertorial is published in The Guardian on June 20th. The text describes Hamlet BioPharmas progress in four key areas:   1. Bladder Cancer: New drug candidate can improve therapy in bladder cancer patients. https://tinyurl.com/bdyyf5u8 2. Bladder Pain Syndrome: How to potentially treat bacterial infections — but without using antibiotics. https://tinyurl.com/

Hamlet BioPharma Participates in The Global Forum 2024

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announce its participation in The Global Forum 2024 By BioStock, set to take place in Lund, Sweden, on May 29-30, 2024. The company will present at 3 pm on Thursday the 30[th] of May. The Global Forum 2024 by BioStock is a premier international event in the life science industry, bringing together industry leaders, researchers, investors, and entrepreneurs to discuss the latest advancements and innovations in biotechnology and medical research. The forum provides a unique

Q3 Interim Report January - March 2024

About Hamlet BioPharma   Hamlet BioPharma is an innovative biotechnology company that develops scientific discoveries into drugs for the treatment of cancer and infections. The goal is to address unmet medical needs in large patient groups in need of improved cancer treatments or alternatives to antibiotics. The company is leveraging highly innovative scientific discoveries and an extensive IP portfolio, to take these innovative drugs through mechanistic and preclinical phases, through the development of drug production technology to the clinic. Three projects in clinical development

Clinical data from patients with bladder pain syndrome support anakinra (IL1-RA) as a new, successful treatment option

Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections - has successfully completed the first part of a controlled clinical trial in patients with bladder pain syndrome (severe pain in the urinary bladder). The patients have been treated with anakinra, which is an Interleukin1 (IL-1) receptor antagonist (IL-1RA). The company can now announce that a significant proportion of the treated patients have responded positively to the treatment. Patients with bladder pain syndrome have severe pain, which is socially

Hamlet BioPharma secures large scale Alpha1 peptide production in an agreement with Polypeptide Group

Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, has secured continued production of Alpha1-peptide with the Swiss public company Polypeptide Group. The new production, at a larger scale, will be essential for the clinical trial program in bladder cancer, currently advancing towards Phase III.Hamlet BioPharma announces an important milestone by advancing pharmaceutical manufacturing of the Alpha1 peptide with the Polypeptide Group, a leading CDMO company in peptide synthesis. Through a cooperative effort with the

Alpha1H to be the first asset for the commercial collaboration

Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces today that the commercial collaborations with Top International Advisory Firms will start with the Alpha 1H Investigational new drug. Hamlet Biopharma entered commercial collaborations with top international advisory firms to enhance partnering and strategic alliances. The collaboration has been initiated with the clinical stage oncology partnering asset with fast-track designation, Alpha 1H. A teaser describing the commercial approach is published on

Immune responses in patients treated with Alpha1H - results published in the journal Cancer Medicine

Hamlet BioPharma announced on January 25 that clinical data showed a strong immune response with anti-tumor potential in Alpha1H-treated patients with bladder cancer. The submitted manuscript has now been approved and published in Cancer Medicine. http://doi.org/10.1002/cam4.7091   The analysis shows an unexpectedly strong immune response in patients treated with Alpha1H. The rapid immune response was activated after the first Alpha1H treatment and persisted during the treatment period. The immune response increased with the treatment dose and has a strong anti-tumor potential. The

Hamlet BioPharma arranges a new series of digital events

Hamlet BioPharma invites you to a series of events aiming to provide insights into the project portfolio’s strong development pipeline, the advanced technologies and the committed and highly competent group of individuals that moves the company forward.   These events will be held on Zoom and open to the public, reflecting the company's commitment to transparency and engagement with the community. The first three presentations are scheduled for April 9th, May 8th, and June 12th.   The presentations represent an opportunity for participants to gain insights into our drug

Hamlet BioPharma Participates in Økonomisk Ugebrev’s Life Science Investor Konference 2024

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, participated in Økonomisk Ugebrev’s Life Science Investor Conference held in Copenhagen on March 20th 2024.   Økonomisk Ugebrev, serves as a platform for collaboration and investment opportunities. Hamlet BioPharma presented the advances made by the company to a diverse audience of industry leaders and investors and the presentation was followed by lively and inspiring discussions.   The video from the event is now available on Hamlet BioPharma’s web site: https://

Hamlet BioPharma Participates in Swiss Nordic Bio 2024

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, is proud to announce its participation in the Swiss Nordic Bio 2024 conference, set to take place in Zurich on March 7, 2024. This high-level partnering and investor conference is dedicated to connecting healthcare innovations, investors, and industry leaders from Switzerland and the Nordic countries. The Swiss Nordic Bio conference gathers Europe's leading executives from the biotech and pharmaceutical sectors, alongside prominent investors. With over 200 participants,

Q2 Interim Report October - December 2023

About Hamlet BioPharma   Hamlet BioPharma is an innovative biotechnology company that develops scientific discoveries into drugs for the treatment of cancer and infections. The goal is to help address unmet medical needs in large patient groups, in need of improved cancer treatments or alternatives to antibiotics. The company is leveraging highly innovative scientific discoveries and an extensive IP portfolio, to take these innovative drugs through mechanistic and preclinical phases, through the development of drug production technology to the clinic. Three projects in clinical

Hamlet BioPharma Enters Commercial Collaborations with Top International Advisory Firms to Enhance Partnering and Strategic Alliances

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, is proud to announce that it has entered into commercial collaborations with two premier international advisory firms. Under the new collaborations, the advisory firms will offer expert support to Hamlet BioPharma, leveraging their global networks and deep industry knowledge to identify and negotiate potential partnerships for commercial opportunities and strategic alliances. “The collaborations are expected to accelerate Hamlet BioPharma’s strategic partnering initiatives

New analyses of clinical data from Alpha1H treated patients with bladder cancer detect a strong immune response with known anti-tumor effects

Hamlet BioPharma’s drug candidate Alpha1H has been shown to affect a majority of tumors in treated patients with cancer of the urinary bladder. A new analysis now provides a further explanation for this strong effect, based on an immune response in the treated patients with known anti-tumor effects. Thus, in addition to killing tumor cells and inducing tumor cell shedding, Alpha1H activates a broad immune response, which adds a strong protective potential against cancer. The manuscript for this study has been submitted for publication.   Alpha1H complex kills several types of cancer

Hamlet BioPharma featured at MSQ’s CEO Webinar series released during the JP Morgan Health Care Conference 2024

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce the webinar, hosted by MSQ ventures in the MSQ’s CEO Webinar series, released during the JP Morgan Health Care Conference 2024, this week.      Register in advance for this webinar:https://us02web.zoom.us/webinar/register/WN_VbVV8FrXTYmtyOF16AmWWw   MSQ Ventures and BioAroundWorld are collaborating to host a bi-weekly MSQ CEO Webinar Series

Immunotherapy - a new approach to treating bacterial infections, including antibiotic resistant strains

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce progress for the treatment of antibiotic resistant bacteria in a murine model relevant to human disease. A recent paper, clearly shows that treatment with the drug anakinra (IL-1RA) prevents severe infections of the urinary tract, including kidney infections that may cause sepsis. The treatment was efficient also against infections caused by antibiotic resistant bacteria,

Antimicrobial peptide therapy for tuberculosis infections

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce progress for the tuberculosis project. A PhD thesis entitled ‘’Antimicrobial peptide therapy for tuberculosis infections’’, from the group of Professor G. Godaly, was successfully defended by Komal Umashankar Rao.Tuberculosis is a major cause of mortality in all parts of the world, not least in patients whose immune system is compromised as in HIV infected individuals. The

Hamlet BioPharma Announces the Nomination of Elisabeth Parker to its Board of Directors

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce the nomination of Dr. Elisabeth Parker to its Board of Directors. Dr. Parker's nomination will bring business development, international pharmaceutical industry networks and leadership excellence to the company and strengthen the continued growth of Hamlet BioPharma. Dr. Elisabeth Parker is currently serving as a Senior Investment Advisor for Healthcare and Life Sciences

Hamlet BioPharma is inviting you to join a digital presentation at Invest Live, Tuesday December 12[th] at 12.00 CET

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted toinvite you to join a presentation at Invest Live, on Tuesday December 12[th]  at 12.00 CET. Gain insights into the company´s latest progress within its infectious disease and cancer therapy, which includes 'Fast Track' status for the company´s cancer-drug Alpha1H. We welcome share holders, investors and other interested parties to join the presentation and discussion. The

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe